SCHEMBL2957896

SCHEMBL2957896

O=C1C=C(Cl)C(=O)c2c(O)cccc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 2/20 1.00
AURKB Q96GD4 2/20 1.00
P4HB P07237 11/20 0.64
MAOA P21397 2/20 0.59
BACE1 P56817 2/20 0.58
MAPT P10636 5/20 0.58
KDM4E B2RXH2 4/20 0.58
RECQL P46063 4/20 0.58
KMT2A Q03164 3/20 0.58
USP2 O75604 2/20 0.58
POLB P06746 2/20 0.58
CTDSP1 Q9GZU7 1/20 0.58
ALDH1A1 P00352 3/20 0.57
HPGD P15428 3/20 0.57
ALOX15 P16050 3/20 0.57
MAPK1 P28482 3/20 0.57
HSD17B10 Q99714 3/20 0.57
TDP1 Q9NUW8 3/20 0.57
SMN1; SMN2 Q16637 2/20 0.57
LMNA P02545 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5084612 0.85 AURKA (0.74) AURKAAURKBP4HBMAOABACE1
SCHEMBL30004050 0.85 AURKA (0.74) AURKAAURKBP4HBMAOABACE1
SCHEMBL5175867 0.81 MAPT (0.72) AURKAAURKBP4HBMAOABACE1
SCHEMBL29728494 0.81 MAPT (0.72) AURKAAURKBP4HBMAOABACE1
SCHEMBL24389157 0.78 P4HB (0.64) AURKAAURKBP4HBMAOABACE1
SCHEMBL29440907 0.78 MAPT (0.74) AURKAAURKBP4HBMAOABACE1
SCHEMBL4304001 0.78 MAPT (0.74) AURKAAURKBP4HBMAOABACE1
SCHEMBL868197 0.78 P4HB (1.00) AURKAAURKBP4HBMAOABACE1
SCHEMBL16879551 0.78 P4HB (0.64) AURKAAURKBP4HBMAOABACE1
SCHEMBL29647673 0.78 P4HB (1.00) AURKAAURKBP4HBMAOABACE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1106375-C Method for preparing substd. anthraguinone and application to preparation of rheins GIREX (FR) 2003-04-23 CN claimed
EP-0909268-B1 METHOD FOR PREPARING SUBSTITUTED ANTHRAQUINONE AND APPLICATION TO THE PREPARATION OF RHEINS GIREX (FR) 2002-06-05 EP claimed
US-6057461-A Method for preparing substituted anthraquinone and application to the preparation of rheins GIREX (FR) 2000-05-02 US claimed
US-5948924-A Process for the preparation of substituted anthraquinones and application in the preparation of rheins GIREX (SOCIETE ANONYME) (FR) 1999-09-07 US claimed
CN-1216035-A METHOD FOR PREPARING SUBSTD. ANTHRAGUINONE AND APPLICATION TO PREPARATION OF RHEINS GIREX (FR) 1999-05-05 CN claimed
US-4895575-A HAIR DYES L'OREAL (FR) 1990-01-23 US claimed
CN-114276227-B Aurora kinase inhibitor and application thereof in preparation of antitumor drugs 山东省千佛山医院 2023-10-13 CN disclosed
CN-105985242-A Preparation method of diacerein 邵阳学院 2016-10-05 CN disclosed
US-7763740-B2 Method for the production of mumbaistatin derivatives SANOFI-AVENTIS (FR) 2010-07-27 US disclosed
US-20090156836-A1 METHOD FOR THE PRODUCTION OF MUMBAISTATIN DERIVATIVES SANOFI-AVENTIS (FR) 2009-06-18 US disclosed
CN-101421222-A Process for the preparation of Mumbaistatin derivatives SANOFI AVENTIS (FR) 2009-04-29 CN disclosed
EP-2010474-A1 METHOD FOR THE PRODUCTION OF MUMBAISTATIN DERIVATIVES Sanofi-Aventis (FR) 2009-01-07 EP disclosed
WO-2007121822-A1 METHOD FOR THE PRODUCTION OF MUMBAISTATIN DERIVATIVES SANOFI-AVENTIS (DE) 2007-11-01 WO disclosed
US-5948924-A Process for the preparation of substituted anthraquinones and application in the preparation of rheins GIREX (SOCIETE ANONYME) (FR) 1999-09-07 US disclosed
CN-1216035-A METHOD FOR PREPARING SUBSTD. ANTHRAGUINONE AND APPLICATION TO PREPARATION OF RHEINS GIREX (FR) 1999-05-05 CN disclosed
EP-0909268-A1 METHOD FOR PREPARING SUBSTITUTED ANTHRAQUINONE AND APPLICATION TO THE PREPARATION OF RHEINS Girex (FR) 1999-04-21 EP disclosed
WO-1998033757-A1 METHOD FOR PREPARING SUBSTITUTED ANTHRAQUINONE AND APPLICATION TO THE PREPARATION OF RHEINS GIREX (FR) 1998-08-06 WO disclosed
EP-0801639-A1 METHOD FOR PREPARING SUBSTITUTED ANTHRAQUINONES AND USE THEREOF FOR PREPARING RHEINS Girex (FR) 1997-10-22 EP disclosed
WO-1997016404-A1 METHOD FOR PREPARING SUBSTITUTED ANTHRAQUINONES AND USE THEREOF FOR PREPARING RHEINS GIREX (FR) 1997-05-09 WO disclosed
US-4895575-A HAIR DYES L'OREAL (FR) 1990-01-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156836-A1 METHOD FOR THE PRODUCTION OF MUMBAISTATIN DERIVATIVES MMAB, MLYCD, HMBS AURKA 50/4885AURKB 9/4885P4HB 354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.